GlassScriptPhysician profile
Erwin Richard Lochte
NPI 1740205533
$5,200.52
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,789 · 2020: $1,498 · 2021: $812 · 2022: $102.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,645.51 | 2019-2021 | |
| Lilly USA, LLC | $565.34 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $443.67 | 2019-2020 | |
| Allergan, INC. | $410.11 | 2019-2020 | |
| Amgen INC. | $348.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $224.24 | 2019-2021 | |
| Pfizer INC. | $195.91 | 2019-2020 | |
| Abbott Laboratories | $169.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.39 | 2019 | |
| Glaxosmithkline, LLC. | $132.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $126.22 | 2019-2021 | |
| Duchesnay USA Incorporated | $124.83 | 2019 | |
| Astellas Pharma US INC | $115.47 | 2019-2022 | |
| Novo Nordisk INC | $89.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.84 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $74.01 | 2019-2021 | |
| Abbvie INC. | $66.09 | 2019-2021 | |
| Bausch Health US, LLC | $60.47 | 2019 | |
| Shire North American Group INC | $33.27 | 2019 | |
| Si-Bone, INC. | $19.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.52 | 2021 | |
| Neos Therapeutics, LP | $17.47 | 2021 | |
| Althera Pharmaceuticals LLC | $15.71 | 2021 | |
| Eisai INC. | $15.41 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.27 | 2019 | |
| Vistapharm, INC. | $15.00 | 2021 | |
| Biogen, INC. | $14.36 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.30 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Lochte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.